Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837993 · ClinicalTrials.gov registry record
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 241
- Enrollment target
NCT00837993: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00837993 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 241 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837993 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 241 participants
- Enrollment target
Study Summary
Primary Objective: * To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system. Secondary Objective: * To determine the overall and progression-free survival of patients with serous carcinoma of the ovary treated on GOG protocol 158 when reclassified according to tumor grade (low vs. high). Tertiary Objective: * To correlate histologic grade with other prognostic factors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837993
The ClinicalTrials.gov registry entry for NCT00837993 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00837993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00837993 about?
NCT00837993 is a clinical study titled "Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System". Primary Objective: * To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system. Secondary Objective: * To determine the overall and progression-free survival of patients with serous carci...
What is the current status of trial NCT00837993?
This trial is currently completed. The enrollment target is 241 participants. The study started on 2007-08. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT00837993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.